Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study.
Chiara CremoliniMatteo BenelliElisa FontanaFilippo PaganiDaniele RossiniGiovanni FucàAdele BusicoElena ConcaSamantha Di DonatoFotios LoupakisMarta SchirripaSara LonardiBeatrice BorelliElena OngaroKatherine EasonFederica MoranoMariaelena CasagrandeMatteo FassanAnguraj SadanandamFilippo de BraudAlfredo FalconeFilippo PietrantonioPublished in: ESMO open (2019)
RAS/BRAF wild-type MSS mTCCs may be sensitive to anti-EGFRs, as confirmed by molecular analyses.